Cargando…

Correction: NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo

Detalles Bibliográficos
Autores principales:	Jalili, Ahmad, Mertz, Kirsten D., Romanov, Julia, Wagner, Christine, Kalthoff, Frank, Stuetz, Anton, Pathria, Gaurav, Gschaider, Melanie, Stingl, Georg, Wagner, Stephan N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770810/ http://dx.doi.org/10.1371/annotation/ddd22094-5d8d-43ef-ad81-b95afe392ec7

Ejemplares similares

NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo
por: Jalili, Ahmad, et al.
Publicado: (2013)

Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
por: Irvine, David A., et al.
Publicado: (2016)

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
por: D'Amato, C, et al.
Publicado: (2014)

Combined effects of the hedgehog pathway inhibitor LDE225 and nilotinib in a random mutagenesis screen
por: Tauchi, Tetsuzo
Publicado: (2012)

Identification of a potent antagonist of smoothened in hedgehog signaling
por: Fan, Junwan, et al.
Publicado: (2021)

A Potent Antagonist of Smoothened in Hedgehog Signaling for Epilepsy
por: Fan, Junwan, et al.
Publicado: (2022)

Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Pijnappel, Esther N., et al.
Publicado: (2021)

Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma
por: Jalili, Ahmad, et al.
Publicado: (2012)

NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128
por: Nanta, R, et al.
Publicado: (2013)

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy
por: Ross, Ashley E., et al.
Publicado: (2017)

Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors
por: Pietrobono, Silvia, et al.
Publicado: (2018)

Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
por: Lonardo, Amedeo
Publicado: (2021)

Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks
por: Migden, Michael, et al.
Publicado: (2022)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists
por: Frank-Kamenetsky, Maria, et al.
Publicado: (2002)

Do LDE-Methotrexate lipid nanoparticles decrease allograft vasculopathy in rabbit transplanted heart ?
por: Stolf, N, et al.
Publicado: (2013)

Deciphering the Allosteric Effect of Antagonist Vismodegib on Smoothened Receptor Deactivation Using Metadynamics Simulation
por: An, Xiaoli, et al.
Publicado: (2019)

The Role of Smoothened in Cancer
por: Jeng, Kuo-Shyang, et al.
Publicado: (2020)

Análisis del Dominio de la Robótica para la propuesta de un LDE /
por: Cuéllar Hernández, Leticia
Publicado: (2002)

A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo
por: Zárate, Ana María, et al.
Publicado: (2021)

Impact of the Smoothened Inhibitor, IPI-926, on Smoothened Ciliary Localization and Hedgehog Pathway Activity
por: Peluso, Marisa O., et al.
Publicado: (2014)

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations
por: GALIMBERTI, FABRIZIO, et al.
Publicado: (2012)

Desarrollo de auditoría interna parcial lde una empresa comercializadora de carne de res
por: Argüelles López, Raquel
Publicado: (1999)

ISoLDE: a data-driven statistical method for the inference of allelic imbalance in datasets with reciprocal crosses
por: Reynès, Christelle, et al.
Publicado: (2019)

A Novel Synthetic Smoothened Antagonist Transiently Inhibits Pancreatic Adenocarcinoma Xenografts in a Mouse Model
por: Strand, Martin F., et al.
Publicado: (2011)

Oxysterols are allosteric activators of the oncoprotein Smoothened
por: Nachtergaele, Sigrid, et al.
Publicado: (2012)

Mechanisms of Smoothened Regulation in Hedgehog Signaling
por: Zhang, Jie, et al.
Publicado: (2021)

Impact of a Mobile Application for Tracking Nausea and Vomiting During Pregnancy (NVP) on NVP Symptoms, Quality of Life, and Decisional Conflict Regarding NVP Treatments: MinSafeStart Randomized Controlled Trial
por: Ngo, Elin, et al.
Publicado: (2022)

Review of NVP and HG and Early Pharmacotherapeutic Intervention
por: Clark, Shannon M., et al.
Publicado: (2012)

Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model
por: Lauressergues, Emilie, et al.
Publicado: (2016)

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
por: Jensen, Michael Rugaard, et al.
Publicado: (2008)

Smoothened gene alterations in keratocystic odontogenic tumors
por: Rui, Zhang, et al.
Publicado: (2014)

Regulation of Smoothened Trafficking and Abundance in Hedgehog Signaling
por: Jia, Jianhang, et al.
Publicado: (2022)

Authorship Correction: Impact of a Mobile Application for Tracking Nausea and Vomiting During Pregnancy (NVP) on NVP Symptoms, Quality of Life, and Decisional Conflict Regarding NVP Treatments: MinSafeStart Randomized Controlled Trial
por: Ngo, Elin, et al.
Publicado: (2022)

Complex Crystal Structure Determination of Hsp90(N)-NVP-AUY922 and In Vitro Anti-NSCLC Activity of NVP-AUY922
por: He, Chun-Xia, et al.
Publicado: (2022)

ACCIDENTA C-225
por: Departments, HR
Publicado: (2010)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia–lymphoma cells
por: Taniguchi, Hiroaki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0lig8742d5t3j8j1nltdk0rmsa